| Literature DB >> 35519414 |
Nehal F Farid1, Nada S Abdelwahab1,2.
Abstract
Recently, the use of antibiotics has become widespread all over the world resulting in bacterial resistance to these antibiotics, which requires alternative medications or higher doses of antibiotics. Implementation of an easy analytical method that can analyze a wide range of β-lactam antibiotics in a single run is important to reduce the time of therapeutic drug monitoring (TDM) in hospitals and minimize the spreading of bacterial resistance. A novel environmentally harmless HPTLC method was developed and validated following FDA recommendations for analysis of four β-lactams; cefaclor, cefotaxime, cefepime, and meropenem, in human plasma. A solvent mixture of ethylacetate : methanol : deionized water : formic acid (60 : 30 : 15 : 1, by volume) was the used developing system, detection was carried out at 270 nm, and valacyclovir was used as an internal standard. A lower limit of quantitation (LLOQ) was found to be 0.1 μg per band for all the analyzed drugs. Validation parameters were calculated and found to fulfil the international requirements for bio-analytical method validation. Additionally, each of the studied antibiotics was given to a group of healthy volunteers from which blood samples were collected at t max of each, methanol was used for precipitation of plasma protein, and the developed method was used for calculation of the concentrations in the separated plasma samples. The developed method, being a green one, and time and money saving, can be used for TDM of these drugs in clinical studies as well as for quality control analysis in pharmaceutical companies. The proposed method is the first developed HPTLC method for the simultaneous bio-analysis of the selected β-lactams. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35519414 PMCID: PMC9065318 DOI: 10.1039/c9ra02671a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 12D chromatogram of (A) blank plasma, (B) plasma sample spiked with a mixture of the studied drugs (at their LLOQ) and internal standard.
Assay and method validation parameters for the determination of the studied drugs by the proposed methoda
| Parameters | Pure samples | Spiked human plasma samples | ||||||
|---|---|---|---|---|---|---|---|---|
| Cefaclor | Cefotaxime | Cefepime | Meropenem | Cefaclor | Cefotaxime | Cefepime | Meropenem | |
| Range, μg per band | 0.06–3.0 | 0.1–3.0 | ||||||
| Slope | −0.0661a | −0.1419a | −0.0891a | −0.0503a | −0.0328a | −0.0103a | −0.0301a | −0.0560a |
| 0.6292b | 1.0245b | 0.4649b | 0.4006b | 0.4271b | 0.4765b | 0.4218b | 0.4423b | |
| Intercept | 0.0059 | 0.0195 | 0.0288 | 0.0151 | −0.0048 | 0.0095 | 0.0468 | 0.0421 |
| Correlation ( | 0.9996 | 0.9998 | 0.9996 | 0.9994 | 0.9996 | 0.9998 | 0.9993 | 0.9994 |
| LLOQ | — | 0.10 | ||||||
| ULOQ | — | 3.00 | ||||||
The linearity was achieved using the polynomial regression equation: A = aX2 + bX + C. a: coefficient 1. b: coefficient 2. A = peak area ratio (peak area of the analyte/peak area of IS), X= concentration μg per band. C = intercept.
Fig. 22D chromatogram of real plasma samples obtained from healthy volunteers at their tmax.
Intra and inter assay precision and accuracy
| Component | Concentration | Intraday | Interday | ||||
|---|---|---|---|---|---|---|---|
| Recovery% | RSD% | Bias% | Recovery% | RSD% | Bias% | ||
| Cefaclor | 0.10 (LLOQ) | 102.56 | 7.29 | 2.56 | 91.98 | 8.13 | −8.02 |
| 0.60 (LQC) | 108.02 | 2.83 | 8.02 | 99.79 | 8.60 | −0.21 | |
| 1.50 (MQC) | 99.57 | 0.04 | −0.43 | 109.34 | 9.40 | 9.34 | |
| 2.50 (HQC) | 104.64 | 7.49 | 4.64 | 104.86 | 9.72 | 4.86 | |
| Cefotaxime | 0.10 (LLOQ) | 105.5 | 8.47 | 5.75 | 93.07 | 9.63 | −6.93 |
| 0.60 (LQC) | 93.97 | 5.09 | −6.03 | 107.56 | 13.42 | 7.56 | |
| 1.50 (MQC) | 94.32 | 7.92 | −5.68 | 91.48 | 10.09 | −8.52 | |
| 2.50 (HQC) | 99.13 | 6.76 | −0.87 | 89.66 | 7.47 | −10.30 | |
| Cefepime | 0.10 (LLOQ) | 116.77 | 3.91 | 16.77 | 118.46 | 1.84 | 18.46 |
| 0.60 (LQC) | 105.52 | 4.42 | 5.52 | 103.65 | 6.24 | 3.65 | |
| 1.50 (MQC) | 106.34 | 5.77 | 6.34 | 108.67 | 9.55 | 3.65 | |
| 2.50 (HQC) | 96.21 | 6.53 | −3.79 | 95.29 | 9.15 | −4.71 | |
| Meropenem | 0.10 (LLOQ) | 102.56 | 4.57 | 2.56 | 107.22 | 10.53 | 7.22 |
| 0.60 (LQC) | 98.74 | 6.19 | −1.26 | 109.01 | 3.31 | 8.99 | |
| 1.50 (MQC) | 90.00 | 4.20 | −10.00 | 97.67 | 9.17 | −2.33 | |
| 2.50 (HQC) | 106.35 | 0.31 | 6.35 | 99.21 | 8.84 | −0.79 | |
Average of 3 experiments.
Bias = [(measured concentration − nominal concentration)/nominal concentration] × 100.
Extraction recovery results of the studied drugs in spiked human plasma
| Analyte | Concentration of the analyte (μg per band) | % recovery |
|---|---|---|
| Cefaclor | 0.60 | 88.56 |
| 1.50 | 93.25 | |
| 2.50 | 95.57 | |
| Mean ± % RSD | 92.46 ± 3.862 | |
| Cefotaxime | 0.60 | 76.86 |
| 1.50 | 73.19 | |
| 2.50 | 80.80 | |
| Mean ± % RSD | 76.75 ± 4.946 | |
| Cefepime | 0.60 | 91.24 |
| 1.50 | 86.96 | |
| 2.50 | 96.94 | |
| Mean ± % RSD | 91.71 ± 5.459 | |
| Meropenem | 0.60 | 94.95 |
| 1.50 | 95.68 | |
| 2.50 | 97.41 | |
| Mean ± % RSD | 90.01 ± 1.316 | |
| IS | 1.00 | 95.07 ± 2.987 |
Average of 3 determinations.
Stability results of the studied drugs in spiked human plasma at different conditions
| Analyte | % recovery | ||
|---|---|---|---|
| Concentration of the analyte (μg per band) | Three freeze–thaw cycles | Bench top stability | |
| Cefaclor | 0.60 | 103.79 | 96.72 |
| 1.50 | 99.30 | 111.39 | |
| 2.50 | 89.90 | 109.67 | |
| Mean ± % RSD | 97.66 ± 7.256 | 105.93 ± 7.57 | |
| Cefotaxime | 0.60 | 106.89 | 99.63 |
| 1.50 | 97.54 | 107.50 | |
| 2.50 | 98.78 | 96.8 | |
| Mean ± % RSD | 101.07 ± 5.024 | 101.31 ± 5.473 | |
| Cefepime | 0.60 | 108.37 | 89.87 |
| 1.50 | 107.18 | 92.37 | |
| 2.50 | 110.63 | 89.78 | |
| Mean ± % RSD | 108.73 ± 1.612 | 90.67 ± 1.621 | |
| Meropenem | 0.60 | 99.08 | 110.13 |
| 1.50 | 96.24 | 111.33 | |
| 2.50 | 104.79 | 100.00 | |
| Mean ± % RSD | 100.04 ± 4.353 | 107.15 ± 5.808 | |
Average of 3 determinations.
| Volunteers | Expected concentration (μg per band)[ | The found concentration (μg per band) | Expected concentration (μg per band) | The found concentration (μg per band)[ |
|---|---|---|---|---|
| Cefaclor | Cefotaxime | |||
| 1 | 0.454 | 0.480 | 1.020 | 1.120 |
| 2 | 0.476 | 0.800 | ||
| 3 | 0.570 | 1.187 | ||
| 4 | 0.510 | 1.053 | ||
| 5 | 0.560 | 1.144 | ||
| 6 | 0.420 | 1.013 | ||
| Mean ± % RSD | 0.519 ± 10.873 | 1.053 ± 13.184 | ||
| Patients | Expected concentration (μg per band)[ | The found concentration (μg per band) | Expected concentration (μg per band)[ | The found concentration (μg per band) |
|---|---|---|---|---|
| Cefepime | Meropenem | |||
| 1 | 0.787 | 0.890 | 0.700 | 0.575 |
| 2 | 0.720 | 0.712 | ||
| 3 | 0.707 | 0.637 | ||
| 4 | 0.827 | 0.688 | ||
| 5 | 0.613 | 0.588 | ||
| 6 | 0.693 | 0.737 | ||
| Mean ± % RSD | 0.742 ± 13.467 | 0.656 ± 10.170 | ||